Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists
Non-randomised trial
OA: bronze
CC0
⤵ 17 in-corpus citations
AI-generated summary
This study investigated how aromatase inhibitors affect the estrogen surge observed when gonadotropins are administered to patients already undergoing treatment with GnRH agonists.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
This was a preliminary study to determine the effect of aromatase inhibitors in preventing the flare induced by GnRH agonist (GnRH-a) in women with endometriosis (n = 9) or leiomyomata (n = 4) who were given letrozole on the first 5 days of the GnRH-a therapy. Serum LH and FSH levels showed the typical flare 1 day after the injection of the GnRH-a; however, E(2) declined immediately after letrozole administration and was notably suppressed at 1, 2, and 4 days after GnRH-a. No patients complained of clinical symptoms typical of the GnRH-a flare phenomenon.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (26)
- A review of current management of endometriosis in 2006: an evidence-based approach via openalex
- Concomitant treatment of severe uterine adenomyosis in a premenopausal woman with an aromatase inhibitor and a gonadotropin-releasing hormone agonist via openalex
- Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis via openalex
- GnRH analogs: options for endometriosis-associated pain treatment via openalex
- Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders via openalex
- Hormonal and biochemical changes during treatment of endometriosis with the luteinizing hormone-releasing hormone (LH-RH) agonist [D-Trp6,des-Gly-NH2(10)]LH-RH ethylamide via openalex
- Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome via openalex
- Revised American Society for Reproductive Medicine classification of endometriosis: 1996 via openalex
- [Treatment of endometriosis with the GnRH agonist leuprorelin acetate depot (Enatone-Gyn monthly depot): a multicenter study] via openalex
- Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain via openalex
- W173875890 via openalex
- W116864337 via openalex
- W2111301534 via openalex
- W2130005791 via openalex
- W2159608759 via openalex
- W2165684716 via openalex
- W2343033730 via openalex
- W6602628479 via openalex
- W6606967296 via openalex
- W1569246512 via openalex
- W6683236057 via openalex
- W1967877758 via openalex
- W1983655425 via openalex
- W2009298269 via openalex
- W2025609858 via openalex
- W2029727633 via openalex
Cited by (19)
- Guideline No. 468: Clinical Management of Endometriosis 2026
- Lignes directrices de pratique clinique n° 468 : Prise en charge clinique de l'endométriose 2026
- Endometriosis: A Narrative Review 2024
- Efficacy and uterine bleeding patterns in initiating goserelin therapy during different menstrual phases in patients with adenomyosis: a prospective cohort study 2024
- Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix 2023
- Clinical efficacy and safety of trimonthly administration of goserelin acetate 10.8 mg in premenopausal Chinese females with symptomatic adenomyosis: a prospective cohort study 2022
- Uso de inhibidores de la aromatasa en el tratamiento del dolor pélvico asociado a endometriosis: revisión sistemática 2021
- Role of medical treatment of endometriosis 2021
- Uso de inhibidores de la aromatasa en el tratamiento del dolor pélvico asociado a endometriosis: revisión sistemática 2021
- Effect of GnRH agonist and letrozole treatment in women with recurrent implantation failure 2019
- Management of recurrent implantation failure by gonadotropin-releasing hormone agonist and aromatase inhibitor suppression, in women without evidence of endometriosis 2018
- A comparison of two months pretreatment with GnRH agonists with or without an aromatase inhibitor in women with ultrasound-diagnosed ovarian endometriomas undergoing IVF 2018
- New developments in the medical treatment of endometriosis 2017
- Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy 2017
- Medical treatment of ureteral obstruction associated with ovarian remnants and/or endometriosis: report of three cases and review of the literature 2014
- Evidence-based long-term management of endometriosis: Medical therapy and treatment of infertility 2011
- Use of aromatase inhibitors in gynecology 2010
- [Treatment of endometriosis by aromatase inhibitors: efficacy and side effects] 2010
- Aromatase inhibitors: potential reproductive implications 2009
Source provenance
- europepmc
- last seen: 2026-10-16T06:09:50.462052+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:05:50.299847+00:00
License: CC0
· commercial use OK